and Palencia (1953) , while Ryan (1954) , using the drug in combination with sulphonamides, had reported favourably on its use in cases of uveitis with high serum levels of toxoplasma antibodies. The advantage of this substance in evaluating treatment is that it has a low antibacterial activity and, so far as is known, no effect on allergic conditions; hence any improvement in a case as a result of treatment with this drug will almost certainly be due to its effect on the parasites.
In a preliminary report on the use of Daraprim in uveitis (Smith, 1956 ) it was shown that mice could be protected from the lethal effects of toxoplasmic infection by Daraprim.
The results in the first 63 cases of uveitis in the clinical trial to be described here were also reported (Perkins, 1956) , and it was suggested that some cases with a positive dye test were improving more quickly than untreated cases, although this result was not statistically significant.
A further 101 cases have now been studied and the preliminary results confirmed at a higher level of statistical significance.
ARRANGEMENT OF At the first visit to the clinic, a careful history is taken and all patients are given a detailed ophthalmological examination. The pathological examinations are initiated and if the condition is active the patient is included in the trial and given tablets, which may contain Daraprim or an inert substance, with instructions to take one each day for 2 weeks. The tablets are labelled A and B, and distributed according to a random list. The clinician in charge of the patient does not know which of the two tablets the patient has received, so that the results cannot be biased by suggestion.
The patient is seen at the end of 2 weeks, and providing no untoward reactions are reported, the treatment is continued for a further 2 weeks. The patient is seen again and the progress of the condition assessed under the headings of visual acuity, degree of injection, aqueous flare, vitreous flare, subjective response, and objective response.
No attempt has been made to assess the degree of improvement, although in some cases this has been very striking. The cases are divided simply into "improved"-in which definite objective signs could be found-and "not improved".
After the assessment of the clinical condition the result was correlated with the toxoplasma reaction and the treatment given. Again it must be emphasized that the person making the assessment did not know whether the patient had received Daraprim or the inert tablets, and in the majority of cases the toxoplasma results were also not yet available. The lack of bias in assessment is clearly shown by the remarkably constant ratio of improved to not improved cases in all groups except those with a positive toxoplasmosis test who received Daraprim. Approximately half of all the cases (except this one group) showed improvement at the end of one month. All the patients received conventional medical treatment, such as mydriatics and cortisone, in addition to the tablets. As cortisone is known to cause improvement in some cases of uveitis, the cases were analysed with respect to the numbers receiving this drug. However, the proportion of patients receiving this drug did not differ significantly between the toxoplasma positive and negative, treated and untreated groups.
In Table E these results are analysed into anterior, posterior, and panuveitis, and, although the numbers in each group are too small for the differences to be statistically significant, the figures for the posterior uveitis group (88 8 per cent. improved) do suggest that toxoplasmosis is a very likely aetiological agent.
The results of Daraprim The response to treat- As might be expected, the acute cases in the positive toxoplasma untreated group and the treated and untreated negative toxoplasma cases show a better improvement rate than the chronic cases, and in the positive toxoplasma group the difference between the acute treated and untreated cases is not statistically significant. However, the subacute and chronic positive x2=4-1; 0-02<P<0-05 toxoplasma cases taken together (Table K) show a statistically significant difference between treated and untreated subacute and chronic toxoplasma positive cases.
The following conclusions can be drawn from the above results:
(1) Daraprim had no detectable effect on cases with negative toxoplasma dye test.
(2) Both positive and negative cases showed much the same rate of improvement on control tablets, and this rate was very similar to that obtained in negative cases treated with Daraprim. (3) Only cases with a positive toxoplasma reaction showed any detectable response to Daraprim. DIsCUSSION These results suggest very strongly that toxoplasmosis is an aetiological factor in some 25 per cent. of cases of uveitis with a positive dye test. This in itself is a finding of very great interest and importance but is not of much help in the diagnosis of any individual case.
Detailed consideration of the results of this investigation do, however, give, some indication of the criteria which should be adopted for the diagnosis of toxoplasmic uveitis.
The first factors to be considered are the dye test and complement-fixation results. A comparison of the results of treatment in cases having a low dye-test titre (I:4 to 1: 16) with those in cases with higher titres (Table L) shows no significant difference in their responses to treatment in the group as a whole. The posterior uveitis group shows some tendency to have a larger number of cases with higher titres. A consideration of the clinical categories gives more hopeful information. The fact that the first proved toxoplasmic infections were congenital or neonatal choroidal lesions suggests that it is in the group of posterior uveitis cases that the acquired disease would have a predeliction. This is amply confirmed in the present investigation. The group of posterior uveitis cases showed a high incidence of positive dye tests (79-3 per cent. posterior, 59-2 per cent. anterior) and more than double the percentage of positive complement-fixation tests compared to the anterior uveitis group (24-1 per cent. posterior, 9-2 per cent. anterior), and as previously noted the dye-test titres tended to be higher than in the other groups.
The best response to treatment was also obtained in the posterior uveitis group; although the numbers are too small to show a statistical difference between anterior and posterior groups, it is probably a real difference as shown by the degree of improvement in some of the cases. Although no attempt was made to grade the degree of improvement, some cases showed such marked responses that these were noted; six out of the seventeen cases of posterior uveitis treated with Daraprim were noted as showing marked improvement, as compared with only five out of 33 anterior uveitis casesmore than double the percentage.
The typical lesion in the posterior group was an area of focal choroidoretinitis with marked vitreous haze. When the haze cleared sufficiently it was often noted that the active lesion was sited at the periphery of an old patch of healed choroiditis. Hogan (1956) reported that the consensus of clinical opinion at the conference on toxoplasmosis was that the condition could not be diagnosed definitely on clinical grounds. Acute and recurrent large foci of chorio-retinal inflammation with heavy opacification of the vitreous were more characteristic of lesions believed to be toxoplasmic.
The position with regard to this type of case seems quite clear and it is apparent that such cases with a positive dye test should be considered to be due to toxoplasmosis and treated as such unless some other aetiology can be proved. It is of interest in this connection to examine the results in nine of the cases of posterior uveitis which were thought, on clinical grounds, to be associated with tuberculosis: seven out of the nine had positive dye tests, four of these improved on treatment with Daraprim, and none failed to respond; one improved and two failed to improve on control tablets. The anterior uveitis cases present more of a problem. Nearly 60 per cent. of this group had a positive dye test and 25 out of 33 improved on Daraprim as compared with twelve out of 25 treated with control tablets. This difference is not quite significant statistically (x2 = 3 *5) but is strongly suggestive, and there seems every likelihood that some of these cases are due to toxoplasmosis. It has not, however, been possible to find any clear correlation between the clinical findings and the toxoplasma results, but it is possible that when larger numbers have been treated some clinical features of the toxoplasmic cases will become apparent.
The last clinical category of generalized uveitis shows the least evidence of toxoplasmosis as an aetiological agent. The percentage of positive dye tests (45 -9 per cent.) is, however, probably higher than the normal population, but the response to treatment with Daraprim shows no better result than the control group. It seems unlikely, therefore, that cases of generalized uveitis are due to toxoplasmosis.
An interesting speculation which the results of this investigation arouses is the part toxoplasmosis may play in other diseases of uncertain aetiology. Infection with toxoplasmosis is widespread in the population', as evidenced by the "normal" 25 per cent. or more positive dye tests, yet apart from the rare acute cases in adults and the congenital cases, the organism has never been incriminated in any disease except uveitis. Are some of the conditions traditionally associated with uveitis also due to toxoplasmosis? Such a question cannot be answered from the data available at the moment but might well repay further investigation.
Toxic Effects of Daraprim.-After the first twenty patients had received Daraprim, it was noted that the dose of 25 mg. daily was sufficient to depress erythropoiesis in about one-third of the cases; this finding is in contrast to that of Ryan, Hart, Culligan, Gunkel, Jacobs, and Cook (1954) , who observed this side-effect only with doses of 75 mg. daily, whereas a reduction of dosage to 25 mg. resulted in recovery. Subsequently full blood counts were carried out at regular intervals on both the Daraprim and control patients, and the records of 193 cases showed the following results:
Of 113 patients receiving Daraprim, the haemoglobin level dropped more than 5 per cent. in 53 (47 per cent.), 23 of whom showed macrocytes in the blood film. The haemoglobin level of the most severely affected case fell from 100 to 83 per cent. in 3 weeks, the anaemia being of the macrocytic normochromic type. In addition, three of these cases showed a slight fall in the leucocyte count with an absolute neutropenia.
Of seventy control patients receiving an inert substance, not one showed evidence of leucocyte depression, although the haemoglobin level of ten (14-3 per cent.) of them dropped by more than 5 per cent. during the course, but in none was there evidence of macrocytosis.
It is clear, therefore, that Daraprim administration should be accompanied by regular blood examinations in order to detect macrocytic anaemia at an early stage, for if this is found to be progressive it may be wiser to discontinue the course, or alternatively the drug may be given with folic acid, which does not apparently interfere with the antitoxoplasma effect of Daraprim. Folic acid was not used in our investigations and the course was discontinued only in the one severe case mentioned above. SUMMARY A controlled clinical trial of Daraprim (pyrimethamine) in cases of active uveitis showed:
(1) Daraprim had no detectable effect on the improvement of cases with a negative toxoplasma reaction. (2) Daraprim exerted a statistically significant effect on the improvement of cases having a positive toxoplasma reaction. 
